Список литературы

Поставить закладку

Owen R.G. et al. Clinicopathological deﬁnition of Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia // Seminars in Oncology. W.B. Saunders, 2003. Vol. 30, № 2. P. 110–115.
Kumar S.K. et al. Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). 2020.
Балакирева Т.В., Андреева Н.Е. Макроглобулинемия Вальденстрема // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009. Vol. 2, № 2. P. 121–136.
Varettoni M. et al. Prevalence and clinical signiﬁcance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms // Blood. American Society of Hematology, 2013. Vol. 121, № 13. P. 2522–2528.
Treon S.P. et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia // N. Engl. J. Med. Massachussetts Medical Society, 2012. Vol. 367, № 9. P. 826–833.
Morel P. et al. International prognostic scoring system for Waldenström macroglobulinemia // Blood. 2009. Vol. 113, № 18. P. 4163–4170.
Kastritis E. et al. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2018. Vol. 29, № Supp. 4. P. iv41–iv50.
Kastritis E. et al. Prognostication in young and old patients with Waldenström’s macroglobulinemia: Importance of the international prognostic scoring system and of serum lactate dehydrogenase // Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, № 1. P. 50–52.
Демина Е.А. et al. Общие принципы диагностики лимфом // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 9–27.
Auwerda J.J.A. et al. Prothrombotic coagulation abnormalities in patients with paraprotein- producing B-cell disorders. // Clin. Lymphoma Myeloma. 2007. Vol. 7, № 7. P. 462–466.
Rothschild B.M., Ruhli F., Rothschild C. Skeletal clues apparently distinguishing Waldenstrom’s macroglobulinemia from multiple myeloma and leukemia // Am. J. Hum. Biol. Wiley-Blackwell, 2002. Vol. 14, № 4. P. 532–537.
Rausch P.G., Herion J.C. Pulmonary manifestations of waldenstrom macroglobulinemia // Am. J. Hematol. John Wiley & Sons, Ltd, 1980. Vol. 9, № 2. P. 201–209.
Kyle R.A. et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia // Seminars in Oncology. W.B. Saunders, 2003. Vol. 30, № 2. P. 116–120.
Owen R.G. et al. Waldenström macroglobulinemia: Development of diagnostic criteria and identiﬁcation of prognostic factors // Am. J. Clin. Pathol. 2001. Vol. 116, № 3. P. 420–428.
Palladini G. et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis // Circulation. Lippincott Williams and Wilkins, 2003. Vol. 107, № 19. P. 2440–2445.
Menke M. et al. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström’s macroglobulinemia // Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, № 1. P. 100–103.
Brandefors L. et al. Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study // Br. J. Haematol. Blackwell Publishing Ltd, 2018. Vol. 183, № 4. P. 564–577.
Dimopoulos M.A. et al. Predictive factors for response to rituximab in Waldenstrom’s macroglobulinemia. // Clin. Lymphoma. 2005. Vol. 5, № 4. P. 270–272.
Treon S.P. et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 // J. Clin. Oncol. 2009. Vol. 27, № 23. P. 3830–3835.
Ghobrial I.M. et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia // Am. J. Hematol. Wiley-Liss Inc., 2010. Vol. 85, № 9. P. 670–674.
Dimopoulos M.A. et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide // J. Clin. Oncol. 2007. Vol. 25, № 22. P. 3344– 3349.
Buske C. et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) // Leukemia. Nature Publishing Group, 2009. Vol. 23, № 1. P. 153–161.
Treon S.P. et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab- containing regimen // Br. J. Haematol. 2011. Vol. 154, № 3. P. 357–362.
Chen C.I. et al. Bortezomib is active in patients with untreated or relapsed Waldenström’s macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group // J. Clin. Oncol. 2007. Vol. 25, № 12. P. 1570–1575.
Paludo J. et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia // Ann. Hematol. Springer Verlag, 2018. Vol. 97, № 8. P. 1417–1425.
Treon S.P. et al. Long-term outcomes to ﬂudarabine and rituximab in Waldenström macroglobulinemia // Blood. 2009. Vol. 113, № 16. P. 3673–3678.
Laszlo D. et al. Rituximab and subcutaneous 2-chloro-2’-deoxyadenosine as therapy in untreated and relapsed Waldenström’s macroglobulinemia // Clinical Lymphoma, Myeloma and Leukemia. 2011. Vol. 11, № 1. P. 130–132.
Tedeschi A. et al. Fludarabine plus cyclophosphamide and rituximab in waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease // Cancer. 2012. Vol. 118, № 2. P. 434–443.
Souchet L. et al. Efﬁcacy and long-term toxicity of the rituximab-ﬂudarabine- cyclophosphamide combination therapy in Waldenstrom’s macroglobulinemia // Am. J. Hematol. Wiley-Liss Inc., 2016. Vol. 91, № 8. P. 782–786.
Kyle R.A. et al. Waldenstrom’s macroglobulinaemia: A prospective study comparing daily intermittent oral chlorambucil // Br. J. Haematol. 2000. Vol. 108, № 4. P. 737–742.
Treon S.P. et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with waldenström macroglobulinemia // J. Clin. Oncol. American Society of Clinical Oncology, 2018. Vol. 36, № 27. P. 2755–2761.
Dimopoulos M.A. et al. Update on treatment recommendations from the fourth international workshop on Waldenström’s macroglobulinemia // Journal of Clinical Oncology. 2009. Vol. 27, № 1. P. 120–126.
Rummel M.J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as ﬁrst-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial // Lancet. Lancet Publishing Group, 2013. Vol. 381, № 9873. P. 1203–1210.
Treon S.P. et al. Bendamustine therapy in patients with relapsed or refractory Waldenström’s macroglobulinemia // Clinical Lymphoma, Myeloma and Leukemia. 2011. Vol. 11, № 1. P. 133–135.
Treon S.P. et al. Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia. Supplemental Appendix. // N. Engl. J. Med. 2015. Vol. 372, № 15. P. 1430–1440.
Treon S.P. How I treat Waldenström macroglobulinemia // Blood. 2009. Vol. 114, № 12. P. 2375–2385.
Балакирева Т.В., Андреева Н.Е. Макроглобулинемия Вальденстрема // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009. Vol. 2(2). P. 121–136.
Ioakimidis L. et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström’s macroglobulinemia // Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, № 1. P. 62–66.
Leblond V. et al. Results of a randomized Trial of Chlorambucil versus Fludarabine for patients with untreated Waldenström Macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma // J. Clin. Oncol. 2013. Vol. 31, № 3. P. 301–307.
Dimopoulos M.A. et al. Treatment of waldenstrom macroglobulinemia with 2- chlorodeoxyadenosine // Ann. Intern. Med. American College of Physicians, 1993. Vol. 118, № 3. P. 195–198.
Dimopoulos M.A. et al. Treatment of Waldenstrom’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identiﬁcation of prognostic factors // Ann. Oncol. 1995. Vol. 6, № 1. P. 49–52.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница